Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination

Gefenaite, Giedre LU orcid ; Tacken, Margot ; Bos, Jens ; Stirbu-Wagner, Irina ; Korevaar, Joke C. ; Stolk, Ronald P. ; Wolters, Bert ; Bijl, Marc ; Postma, Maarten J. and Wilschut, Jan , et al. (2013) In PLoS ONE 8(6).
Abstract

Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza... (More)

Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.Conclusions:Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
in
PLoS ONE
volume
8
issue
6
article number
e66125
publisher
Public Library of Science (PLoS)
external identifiers
  • pmid:23840413
  • scopus:84879269590
ISSN
1932-6203
DOI
10.1371/journal.pone.0066125
project
Newly introduced vaccines: effectiveness and determinants of acceptance
Infectious diseases surveillance, vaccine effectiveness and determinants of acceptance
language
English
LU publication?
no
id
d4c7107d-465c-405f-8ee6-0710dd5b69b6
date added to LUP
2020-05-14 14:24:47
date last changed
2024-01-02 10:58:09
@article{d4c7107d-465c-405f-8ee6-0710dd5b69b6,
  abstract     = {{<p>Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n&gt;25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.Conclusions:Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.</p>}},
  author       = {{Gefenaite, Giedre and Tacken, Margot and Bos, Jens and Stirbu-Wagner, Irina and Korevaar, Joke C. and Stolk, Ronald P. and Wolters, Bert and Bijl, Marc and Postma, Maarten J. and Wilschut, Jan and Nichol, Kristin L. and Hak, Eelko}},
  issn         = {{1932-6203}},
  language     = {{eng}},
  number       = {{6}},
  publisher    = {{Public Library of Science (PLoS)}},
  series       = {{PLoS ONE}},
  title        = {{Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination}},
  url          = {{http://dx.doi.org/10.1371/journal.pone.0066125}},
  doi          = {{10.1371/journal.pone.0066125}},
  volume       = {{8}},
  year         = {{2013}},
}